HER2 is a useful tumor marker for therapeutic decision making for patients with breast cancer. There are several possible uses of HER2 testing in clinical decisions. Because HER2-positive breast cancers tend to be more aggressive, positivity is associated with worse prognosis. Her2-positive patients respond well to certain chemotherapies, such as Herceptin® (trastuzumab).
